Evidence mapPaperPMID 37878066Full record

ArticleDiabetologia2024

The metabolomic signature of weight loss and remission in the Diabetes Remission Clinical Trial (DiRECT).

Laura J Corbin, David A Hughes, Caroline J Bull, Emma E Vincent, Madeleine L Smith, Alex McConnachie, Claudia-Martina Messow, Paul Welsh, Roy Taylor, Michael E J Lean and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Diabetologia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 25 citations in OpenAlex.

  1. Trial
  2. Leveraging Multiomic Signatures to Predict Body Composition.Advances in nutrition (Bethesda, Md.) · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Laura J CorbinMRC Integrative Epidemiology Unit at University of Bristol, Bristol, UK. laura.corbin@bristol.ac.uk.
David A HughesMRC Integrative Epidemiology Unit at University of Bristol, Bristol, UK.
Caroline J BullMRC Integrative Epidemiology Unit at University of Bristol, Bristol, UK.
Emma E VincentMRC Integrative Epidemiology Unit at University of Bristol, Bristol, UK.
Madeleine L SmithMRC Integrative Epidemiology Unit at University of Bristol, Bristol, UK.
Alex McConnachieRobertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
Claudia-Martina MessowRobertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
Paul WelshSchool of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Roy TaylorNewcastle Magnetic Resonance Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
Michael E J LeanHuman Nutrition, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK.
Naveed Sattar *School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Nicholas J Timpson *MRC Integrative Epidemiology Unit at University of Bristol, Bristol, UK.
University of Bristol · GBUniversity of Glasgow · GBAt Bristol · GBNIHR Newcastle Biomedical Research Centre · GB

Funding

Cancer Research UK 29019Diabetes UK 13/0004691Medical Research Council MC_UU_00011Wellcome TrustWellcome Trust 202802/Z/16/Z
6 · The paper itself

Abstract

aims/hypothesisHigh-throughput metabolomics technologies in a variety of study designs have demonstrated a consistent metabolomic signature of overweight and type 2 diabetes. However, the extent to which these metabolomic patterns can be reversed with weight loss and diabetes remission has been weakly investigated. We aimed to characterise the metabolomic consequences of a weight-loss intervention in individuals with type 2 diabetes.

methodsWe analysed 574 fasted serum samples collected within an existing RCT (the Diabetes Remission Clinical Trial [DiRECT]) (N=298). In the trial, participating primary care practices were randomly assigned (1:1) to provide either a weight management programme (intervention) or best-practice care by guidelines (control) treatment to individuals with type 2 diabetes. Here, metabolomics analysis was performed on samples collected at baseline and 12 months using both untargeted MS and targeted

resultsDecreases in branched-chain amino acids, sugars and LDL triglycerides, and increases in sphingolipids, plasmalogens and metabolites related to fatty acid metabolism were associated with the intervention (Holm-corrected p<0.05). In individuals who lost more than 9 kg between baseline and 12 months, those who achieved diabetes remission saw greater reductions in glucose, fructose and mannose, compared with those who did not achieve remission. CONCLUSIONS/

interpretationWe have characterised the metabolomic effects of an integrated weight management programme previously shown to deliver weight loss and diabetes remission. A large proportion of the metabolome appears to be modifiable. Patterns of change were largely and strikingly opposite to perturbances previously documented with the development of type 2 diabetes. DATA AVAILABILITY: The data used for analysis are available on a research data repository ( https://researchdata.gla.ac.uk/ ) with access given to researchers subject to appropriate data sharing agreements. Metabolite data preparation, data pre-processing, statistical analyses and figure generation were performed in R Studio v.1.0.143 using R v.4.0.2. The R code for this study has been made publicly available on GitHub at: https://github.com/lauracorbin/metabolomics_of_direct .

Indexed as

Diabetes Mellitus, Type 2GlucoseHumansMetabolomeMetabolomicsRandomized Controlled Trials as TopicWeight LossGlucoseDiabetes remissionDiRECTMetabolomicsRandomised controlled trialType 2 diabetesWeight loss

Identifiers

PMID37878066
PMCPMC10709482
OpenAlexW4387931602

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.